Trends in Advanced Bio-Manufacturing

Our latest whitepaper from Principal Consultant Tertia Dex offers senior decision-makers a structured view of where biopharmaceutical manufacturing is headed, and what it demands of the facilities being built today.

From the continued dominance of monoclonal antibodies to the explosive growth of cell and gene therapies, the industry is no longer just scaling, it’s restructuring. The paper maps the full modality landscape, from traditional biologics through to CAR-T, CRISPR, viral vectors, and theranostics, and examines the facility, digital, and operational implications of each step up in complexity.

Key topics covered include the comparative market growth of traditional biologics vs. cell and gene therapy, the Asia-Pacific region’s rise as a strategic manufacturing hub, the patient access and pricing pressures reshaping commercial models, and the role of connected infrastructure in making advanced facilities future-ready.